T Spelman, W L Herring, C Acosta, R Hyde, V G Jokubaitis, E Pucci, A Lugaresi, G Laureys, E K Havrdova, D Horakova, G Izquierdo, S Eichau, S Ozakbas, R Alroughani, T Kalincik, P Duquette, M Girard, T Petersen, F Patti, T Csepany, F Granella, F Grand'Maison, D Ferraro, R Karabudak, M Jose Sa, M Trojano, V van Pesch, B Van Wijmeersch, E Cartechini, P McCombe, O Gerlach, D Spitaleri, C Rozsa, S Hodgkinson, R Bergamaschi, R Gouider, A Soysal, Castillo-Triviño, J Prevost, J Garber, K de Gans, R Ampapa, M Simo, J L Sanchez-Menoyo, G Iuliano, A Sas, A van der Walt, N John, O Gray, S Hughes, G De Luca, M Onofrj, K Buzzard, O Skibina, M Terzi, M Slee, C Solaro, Oreja-Guevara, C Ramo-Tello, Y Fragoso, V Shaygannejad, F Moore, C Rajda, E Aguera Morales, H Butzkueven
AIM: To evaluate the real-world comparative effectiveness and the cost-effectiveness, from a UK National Health Service perspective, of natalizumab versus fingolimod in patients with rapidly evolving severe relapsing-remitting multiple sclerosis (RES-RRMS). METHODS: Real-world data from the MSBase Registry were obtained for patients with RES-RRMS who were previously either naive to disease-modifying therapies or had been treated with interferon-based therapies, glatiramer acetate, dimethyl fumarate, or teriflunomide (collectively known as BRACETD)...
2024: Journal of Medical Economics